Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis.
Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis.
复制标题
肿瘤抗原脉冲 DC 治疗高级别胶质瘤患者的临床疗效：来自荟萃分析的证据
DOI：
10.1371/journal.pone.0107173
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Wang ZX
中科院分区：
文献类型：
--
作者：
Cao JX;Zhang XY;Liu JL;Li D;Li JL;Liu YS;Wang M;Xu BL;Wang HB;Wang ZX
背景免疫治疗对高级别胶质瘤（HGG）患者的有效性仍存在争议。为了评估树突状细胞（DC）单独治疗HGG的疗效，我们对相关已发表的临床研究进行了患者生存率的系统回顾和荟萃分析。材料与方法共409例患者，包括历史队列，非随机和随机对照HGG，被选为荟萃分析。结果与非DC组相比，DC治疗HGG组的1年生存率（OS）（p<0.001）和1.5、2、3、4和5年OS（p<0.001）显著提高。患者结果数据的荟萃分析显示，DC免疫治疗对HGG患者的无进展生存期（PFS）具有显著影响，HGG患者显示1年、1.5年、2年、3年和4年PFS显著改善（p<0.001）。Karnofsky体力状态（KPS）分析显示DC细胞治疗组没有有利的结果（p = 0.23）。DC组中的CD 3 + CD 8+和CD 3 + CD 4 + T细胞百分比以及CD 16+淋巴细胞亚群与治疗前观察到的基线水平相比没有显著增加（p>0.05），而DC治疗后的CD 56+淋巴细胞亚群显著增加（p = 0.0001）。 HGG患者外周血中反映免疫功能的IFN-γ水平在DC免疫治疗后明显升高（P<0.001）。结论DC免疫治疗能显著提高HGG患者的生存率和无进展时间，增强免疫功能，提高HGG患者的治疗效果。
Background The effectiveness of immunotherapy for high-grade glioma (HGG) patients remains controversial. To evaluate the therapeutic efficacy of dendritic cells (DCs) alone in the treatment of HGG, we performed a systematic review and meta-analysis in terms of patient survival with relevant published clinical studies. Materials and methods A total of 409 patients, including historical cohorts, nonrandomized and randomized controls with HGG, were selected for the meta-analysis. Results The treatment of HGG with DCs was associated with a significantly improved one-year survival (OS) (p<0.001) and 1.5-, 2-, 3-, 4-, and 5-year OS (p<0.001) compared with the non-DC group. A meta-analysis of the patient outcome data revealed that DC immunotherapy has a significant influence on progression-free survival (PFS) in HGG patients, who showed significantly improved 1-,1.5-, 2-, 3- and 4-year PFS (p<0.001). The analysis of Karnofsky performance status (KPS) demonstrated no favorable results for DC cell therapy arm (p = 0.23).The percentages of CD3+CD8+ and CD3+CD4+ T cells and CD16+ lymphocyte subset were not significantly increased in the DC group compared with the baseline levels observed before treatment (p>0.05), whereas CD56+ lymphocyte subset were significantly increased after DC treatment (p = 0.0001). Furthermore, the levels of IFN-γ in the peripheral blood of HGG patients, which reflect the immune function of the patients, were significantly increased after DC immunotherapy (p<0.001). Conclusions Thus, our meta-analysis showed that DC immunotherapy markedly prolongs survival rates and progression-free time, enhances immune function, and improves the efficacy of the treatment of HGG patients.
登录
查看更多内容
DOI：
10.1038/nrc3258
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
通讯作者：
--
影响因子：
4.1
作者：
Izumoto, Shuichi;Tsuboi, Akihiro;Yosihmine, Toshiki
通讯作者：
Yosihmine, Toshiki
影响因子：
2.6
作者：
Jie, X.;Hua, L.;Hua, Z.
通讯作者：
Hua, Z.
影响因子：
4.8
作者：
Shah, Ashish H.;Bregy, Amade;Goldberg, John
通讯作者：
Goldberg, John
影响因子：
--
作者：
Jackson C;Ruzevick J;Phallen J;Belcaid Z;Lim M
通讯作者：
Lim M